- Trials with a EudraCT protocol (25)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
25 result(s) found for: Anal Canal.
Displaying page 1 of 2.
EudraCT Number: 2009-010976-94 | Sponsor Protocol Number: gi0901 | Start Date*: 2009-07-16 | |||||||||||
Sponsor Name:herlev hospital | |||||||||||||
Full Title: behandling af patienter med avanceret rectumcancer med capecitabin og oxaliplatin før under og efter kurativt intenderet strålebehandling, samt tillæg af cetuximab til patienter der er K-RAS vild-type | |||||||||||||
Medical condition: we will give capecitabine and oxaliplatin togehter with radiation to patient with rectum cancer T3 and T4. We will add cetuximab to patients who are K-RAS wild-type | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-007029-38 | Sponsor Protocol Number: ACCORD 16 / 0708 | Start Date*: 2008-10-03 | |||||||||||
Sponsor Name:FNCLCC | |||||||||||||
Full Title: Essai de phase II multicentrique non randomisée étudiant l’impact de l’association radiochimiothérapie (65 Gy + cisplatine + 5FU) au cetuximab chez les patients présentant un cancer anal localement... | |||||||||||||
Medical condition: Cancers épidermoïdes du canal anal localement avancé | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-005887-24 | Sponsor Protocol Number: GEMCAD-2103//MO44170 | Start Date*: 2022-11-25 | |||||||||||
Sponsor Name:Grupo Español Multidisciplinar de Cáncer Digestivo (GEMCAD) | |||||||||||||
Full Title: Phase II study of Atezolizumab plus Tiraglolumab in combination with chemoradiotherapy in localized squamous cell carcinoma of the anal canal | |||||||||||||
Medical condition: Locallized squamous cell carcinoma of the anal canal in the first-line setting. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-003005-25 | Sponsor Protocol Number: RADIANCE | Start Date*: 2019-12-17 | ||||||||||||||||
Sponsor Name:University Hospital Frankfurt, Goethe University | ||||||||||||||||||
Full Title: Radiochemotherapy +/- Durvalumab for locally-advanced Anal Carcinoma A multicenter, randomized, phase II trial of the German Anal Cancer Study Group | ||||||||||||||||||
Medical condition: anal cancer (UICC-Stage IIB-IIIC, incl. T2>4cm Nany ) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Ongoing) AT (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-001581-32 | Sponsor Protocol Number: 06/0171 | Start Date*: 2008-01-22 |
Sponsor Name:Joint UCLH & UCL Biomedical Research Unit | ||
Full Title: Phase I trial of photodynamic therapy using systemic 5-aminolaevulinic acid for the treatment of grade 3 anal intraepithelial neoplasia. | ||
Medical condition: Grade 3 anal intraepithelial neoplasia | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2011-000948-18 | Sponsor Protocol Number: VICORYX | Start Date*: 2011-08-25 | ||||||||||||||||||||||||||||||||||||
Sponsor Name:Oryx GmbH & Co. KG | ||||||||||||||||||||||||||||||||||||||
Full Title: Phase I/IIa study of immunization with a p16INK4a peptide combined with MONTANIDE ISA-51 VG in patients with advanced HPV-associated cancers | ||||||||||||||||||||||||||||||||||||||
Medical condition: advanced HPV- and p16INK4a-positive cervical, vulvar, vaginal, penile, anal or head and neck cancer | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
Trial protocol: DE (Completed) | ||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-003351-65 | Sponsor Protocol Number: RDD110 | Start Date*: 2016-03-16 |
Sponsor Name:RDD Pharma Ltd. | ||
Full Title: The Effect of Intra-anal Nifedipine, Used As Add-on to Conservative Therapy, on Pain in Patients with Anal Fissure | ||
Medical condition: Anal Fissure | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BG (Completed) PL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2020-000826-24 | Sponsor Protocol Number: INCMGA0012-303 | Start Date*: 2020-10-29 | |||||||||||
Sponsor Name:Incyte Corporation | |||||||||||||
Full Title: A Phase 3 Global, Multicenter, Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carc... | |||||||||||||
Medical condition: Male and female participants at least 18 years of age who have inoperable locally recurrent or metastatic Squamous Carcinoma of the Anal Canal (SCAC) not previously treated with systemic chemotherapy. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Ongoing) GB (GB - no longer in EU/EEA) NO (Ongoing) DE (Ongoing) FR (Ongoing) DK (Trial now transitioned) IT (Ongoing) SE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-004749-33 | Sponsor Protocol Number: 1381-0011 | Start Date*: 2020-06-22 | |||||||||||
Sponsor Name:Boehringer Ingelheim Norway KS | |||||||||||||
Full Title: An open label, randomized Phase II study of BI 754091 alone or in combination with BI 836880 in patients with chemotherapy resistant, unresectable, metastatic squamous cell carcinoma of the anal canal | |||||||||||||
Medical condition: metastatic squamous cell carcinoma of the anal canal | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NO (Completed) BE (Completed) FI (Prematurely Ended) SE (Prematurely Ended) PT (Prematurely Ended) DE (Completed) LV (Prematurely Ended) AT (Prematurely Ended) PL (Prematurely Ended) GB (Prematurely Ended) NL (Prematurely Ended) FR (Completed) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-003767-39 | Sponsor Protocol Number: 955/08 | Start Date*: 2008-09-14 | |||||||||||
Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI | |||||||||||||
Full Title: Concomitant radiochemotherapy with Tegafur and Mitomycin in locally advanced anal canal cancer: Dose Escalation Study. | |||||||||||||
Medical condition: locally advanced squamous anal canal cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-018430-48 | Sponsor Protocol Number: GEMCAD-09-02 | Start Date*: 2010-05-20 |
Sponsor Name:Grupo Español Multidisciplinar en cáncer Digestivo-GEMCAD | ||
Full Title: Estudio de fase II para evaluar la eficacia y la seguridad de la quimiorradioterapia con 5-fluorouracilo, mitomicina C y panitumumab como tratamiento del carcinoma anal de células escamosas | ||
Medical condition: Tratamiento de primera línea para pacientes con cáncer de células escamosas del canal anal locorregional | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2017-003185-27 | Sponsor Protocol Number: C17-02 | Start Date*: 2018-04-18 | |||||||||||
Sponsor Name:GERCOR | |||||||||||||
Full Title: A non-comparative randomized 2:1 phase II study of docetaxel, cisplatin, and 5-fluorouracil in combination or not with atezolizumab in patients with metastatic or unresectable locally advanced squa... | |||||||||||||
Medical condition: Metastatic or unresectable locally advanced squamous anal carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-002070-51 | Sponsor Protocol Number: INCMGA0012-202 | Start Date*: 2019-07-10 | |||||||||||
Sponsor Name:Incyte Corporation | |||||||||||||
Full Title: A Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy (POD1UM 202) | |||||||||||||
Medical condition: Squamous Carcinoma of the Anal Canal | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) BE (Completed) GB (GB - no longer in EU/EEA) DE (Completed) IT (Completed) DK (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-000881-39 | Sponsor Protocol Number: P/2019/418 | Start Date*: 2019-12-10 |
Sponsor Name:CHU de Besançon | ||
Full Title: A phase II study evaluating the interest to combine UCPVax a CD4 TH1-inducer cancer vaccine and atezolizumab for the treatment of HPV positive cancers | ||
Medical condition: cancers induits par HPV (Human PapillomaVirus) (cancers ORL, du col de l'utérus, de la vulve et du canal anal | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2017-002811-33 | Sponsor Protocol Number: LAINCO1107 | Start Date*: 2017-12-11 | |||||||||||
Sponsor Name:LAINCO S.A | |||||||||||||
Full Title: Unilateral, open and randomized phase IV study of 2 groups to assess the degree of comfort with simple Emuliquen® in patients undergoing proctological surgery | |||||||||||||
Medical condition: Surgery proctological | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-003532-32 | Sponsor Protocol Number: LX1606.1-204-UC | Start Date*: 2011-12-19 | |||||||||||
Sponsor Name:Lexicon Pharmaceuticals, Inc. | |||||||||||||
Full Title: Phase 2 Assessment of the Relationship between Serotonin and Efficacy in Ulcerative Colitis: A Multi-Center Randomized, Double Blind, Placebo-Controlled, Pilot Study to Evaluate Safety and Prelimi... | |||||||||||||
Medical condition: Acute mild to moderate ulcerative colitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SK (Completed) LT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-001376-42 | Sponsor Protocol Number: IC-01-02-5-009 | Start Date*: 2021-10-27 | ||||||||||||||||
Sponsor Name:Innovacell AG | ||||||||||||||||||
Full Title: Skeletal muscle-derived cell implantation for the treatment of fecal incontinence: a phase III, randomized, controlled, double blind, two armed clinical study. | ||||||||||||||||||
Medical condition: Fecal incontinence | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Ongoing) IT (Ongoing) BG (Ongoing) PL (Ongoing) CZ (Ongoing) DE (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-004211-31 | Sponsor Protocol Number: CCR3894 | Start Date*: 2014-08-20 |
Sponsor Name:The Royal Marsden NHS Foundation Trust | ||
Full Title: Randomised double-blind controlled phase II trial of Tocovid SupraBio in combination with pentoxifylline (PTX) in patients suffering long-term adverse effects of radiotherapy for pelvic cancer | ||
Medical condition: Adverse effects of radiotherapy for pelvic cancer. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2008-007412-15 | Sponsor Protocol Number: CSET 2008/1443 | Start Date*: 2009-01-26 | |||||||||||
Sponsor Name:Institut Gustave Roussy | |||||||||||||
Full Title: Essai de phase III comparant la perfusion isolée pelvienne (PIP) avec du TNF-α 0,3 mg et du melphalan 1,5 mg/kg versus traitement standard dans les tumeurs pelviennes localement évoluées d’origine ... | |||||||||||||
Medical condition: Tumeur pelvienne localement évoluée d’origine gynécologique ou digestive | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-003206-25 | Sponsor Protocol Number: NRL001-01/2011(SEFI) | Start Date*: 2012-01-25 | |||||||||||
Sponsor Name:Norgine Ltd | |||||||||||||
Full Title: A multi-centre, phase II, double-blind, randomised, placebo-controlled, parallel group, dose-ranging study in patients with faecal incontinence; to evaluate the efficacy, safety and tolerability of... | |||||||||||||
Medical condition: Faecal incontinence | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) CZ (Completed) DE (Completed) ES (Completed) GB (Completed) IT (Completed) HU (Completed) | |||||||||||||
Trial results: Removed from public view |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.